BRD4 and colonic neoplasm: Likewise, the promoter of the bromodomain protein, BRD4 is hypermethylated in 31%–50% of colon cancers, and AZA can be used to demethylate the promoter resulting in re-expression of BRD4 which impairs tumour growth [39].